olfactory receptor family 5 subfamily G member 3 (gene/pseudogene)Genealiases: []
Q-omics provides the consensus-scored OR5G3 profile across patient tissues and cancer cell-line models. OR5G3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OR5G3 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, OR5G3 RNA expression shows 6,306 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight MESO, LUSC, and KIRC as cancer lineages where OR5G3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5G3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5G3 survival associations across molecular data types. OR5G3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5G3 RNA expression–survival associations across cancer types. High OR5G3 expression shows unfavorable associations in CHOL, THCA and PCPG, but favorable associations in MESO, BRCA and PRAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .017). Together, the overview and detailed table identify MESO as the clearest survival context for OR5G3 RNA expression.
This table summarizes OR5G3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR5G3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5G3 shows lower tumor expression in LUSC, LIHC and THCA and higher tumor expression in KICH and LUAD. The LUSC box plot shows higher OR5G3 RNA expression in normal versus tumor tissue (log2 FC = −0.150, t-test p = .023).
This table shows molecular features associated with OR5G3 in patient tissues and cancer cell lines. In patient samples, OR5G3 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR5G3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN.
